SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/23 Sarepta Therapeutics, Inc. 10-K 12/31/22 119:23M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 6.67M 2: EX-10 Ex-10.70 HTML 50K 3: EX-10 Ex-10.72 HTML 39K 4: EX-10 Ex-10.73 HTML 260K 5: EX-21 Ex-21.1 HTML 33K 6: EX-23 Ex-23.1 HTML 32K 7: EX-31 Ex-31.1 HTML 36K 8: EX-31 Ex-31.2 HTML 36K 9: EX-32 Ex-32.1 HTML 35K 10: EX-32 Ex-32.2 HTML 35K 16: R1 Document and Entity Information HTML 103K 17: R2 Consolidated Balance Sheets HTML 138K 18: R3 Consolidated Balance Sheets (Parenthetical) HTML 50K 19: R4 Consolidated Statements of Operations and HTML 137K Comprehensive Loss 20: R5 Consolidated Statements of Stockholders' Equity HTML 100K 21: R6 Consolidated Statements of Cash Flows HTML 171K 22: R7 Organization and Nature of Business HTML 40K 23: R8 Summary of Significant Accounting Policies and HTML 134K Recent Accounting Pronouncements 24: R9 License and Collaboration Agreements HTML 125K 25: R10 Gain From Sale of Priority Review Voucher HTML 37K 26: R11 Fair Value Measurements HTML 258K 27: R12 Cash, Cash Equivalents and Marketable Securities HTML 198K 28: R13 Product Revenues, Net, Accounts Receivable and HTML 146K Reserves for Product Revenues 29: R14 Inventory HTML 80K 30: R15 Other Assets HTML 118K 31: R16 Property and Equipment, Net HTML 91K 32: R17 Intangible Assets, Net HTML 94K 33: R18 Accrued Expenses HTML 87K 34: R19 Indebtedness HTML 175K 35: R20 Equity HTML 44K 36: R21 Stock-Based Compensation HTML 288K 37: R22 401 (K) Plan HTML 41K 38: R23 Other (Loss) Income, Net HTML 102K 39: R24 Income Taxes HTML 335K 40: R25 Leases HTML 128K 41: R26 Net Loss Per Share HTML 80K 42: R27 Commitments and Contingencies HTML 91K 43: R28 Summary of Significant Accounting Policies and HTML 189K Recent Accounting Pronouncements (Policies) 44: R29 Summary of Significant Accounting Policies and HTML 50K Recent Accounting Pronouncements (Tables) 45: R30 Fair Value Measurements (Tables) HTML 254K 46: R31 Cash, Cash Equivalents and Marketable Securities HTML 197K (Tables) 47: R32 Product Revenues, Net, Accounts Receivable and HTML 131K Reserves for Product Revenues (Tables) 48: R33 Inventory (Tables) HTML 82K 49: R34 Other Assets (Tables) HTML 119K 50: R35 Property and Equipment, Net (Tables) HTML 88K 51: R36 Intangible Assets, Net (Tables) HTML 87K 52: R37 Accrued Expenses (Tables) HTML 86K 53: R38 Indebtedness (Tables) HTML 114K 54: R39 Stock-Based Compensation (Tables) HTML 272K 55: R40 Other (Loss) Income, Net (Tables) HTML 101K 56: R41 Income Taxes (Tables) HTML 322K 57: R42 Leases (Tables) HTML 112K 58: R43 Net Loss Per Share (Tables) HTML 78K 59: R44 Commitments and Contingencies (Tables) HTML 54K 60: R45 Organization and Nature of Business - Additional HTML 44K Information (Detail) 61: R46 Summary of Significant Accounting Policies and HTML 90K Recent Accounting Pronouncements - Additional Information (Detail) 62: R47 Summary of Estimated Useful Lives of Plant and HTML 57K Equipment (Detail) 63: R48 License and Collaboration Agreements - Additional HTML 317K Information (Detail) 64: R49 Gain from Sale of Priority Review Voucher - HTML 35K Additional Information (Detail) 65: R50 Assets and Liabilities Measured and Carried at HTML 71K Fair Value (Detail) 66: R51 Summary of Fair Value of Level 3 Financial Assets HTML 41K (Details) 67: R52 Summary of Fair Value of Level 3 Financial HTML 42K Liabilities (Detail) 68: R53 Fair Value Measurements - Additional Information HTML 36K (Detail) 69: R54 Summary of Company Financial Assets with HTML 43K Maturities of Less Than 90 Days Included in Cash Equivalents (Detail) 70: R55 Cash, Cash Equivalents and Marketable Securities - HTML 36K Additional Information (Detail) 71: R56 Summary of Company Cash, Cash Equivalents and HTML 81K Investments (Detail) 72: R57 Product Revenues, Net, Accounts Receivable and HTML 70K Reserves for Product Revenues (Additional Information) (Details) 73: R58 Summary of product revenues, net by product HTML 37K (Details) 74: R59 Summary of Components of Accounts Receivable HTML 36K (Detail) 75: R60 ACCOUNTS RECEIVABLE AND RESERVES FOR PRODUCT HTML 52K REVENUES - Summary of Change in Reserves for Discounts and Allowances (Detail) 76: R61 ACCOUNTS RECEIVABLE AND RESERVES FOR PRODUCT HTML 38K REVENUES - Summary of Total Reserves Included in Consolidated Balance Sheets (Detail) 77: R62 INVENTORY - Summary of Components of Inventory HTML 41K (Detail) 78: R63 INVENTORY - Summarizes The Balance Sheet HTML 38K Classification (Details) 79: R64 OTHER ASSETS - Summary of Other Current Assets HTML 55K (Detail) 80: R65 OTHER ASSETS - Summary of Other Non-current Assets HTML 46K (Detail) 81: R66 Summarizes Components of Property and Equipment, HTML 60K Net (Detail) 82: R67 Property and Equipment, Net - Additional HTML 34K Information (Detail) 83: R68 Intangible Assets, Net - Summary of Components of HTML 46K Intangible Assets (Detail) 84: R69 Intangible Assets, Net - Additional Information HTML 59K (Detail) 85: R70 Intangible Assets, Net - Summary of Estimated HTML 47K Future Amortization for Intangible Assets (Detail) 86: R71 ACCRUED EXPENSES - Summary of Accrued Expenses HTML 57K (Detail) 87: R72 Indebtedness - Additional Information (Detail) HTML 197K 88: R73 Indebtedness - Summary of Debt Facilities (Detail) HTML 58K 89: R74 Indebtedness - Summarizes Total Gross Payments Due HTML 52K under Company's Debt Arrangements (Detail) 90: R75 Equity - Additional Information (Detail) HTML 49K 91: R76 Stock Based Compensation - Additional Information HTML 139K (Detail) 92: R77 Assumptions for Measuring Fair Values of Stocks HTML 54K (Detail) 93: R78 Assumptions for Measuring Fair Values of Stocks HTML 34K (Parenthetical) (Detail) 94: R79 Summary of Stock Option Activity (Detail) HTML 83K 95: R80 Summary of Company's Stock Options Vested and HTML 36K Exercised (Detail) 96: R81 Summary of Restricted Stock Unit Activity (Detail) HTML 58K 97: R82 Summary of Employee Stock Purchase Plan Activity HTML 38K and Expense (Detail) 98: R83 Summary of Stock-Based Compensation Expense by HTML 39K Function Included within Consolidated Statements of Operations and Comprehensive Loss (Detail) 99: R84 Summary of Stock-Based Compensation Expense by HTML 42K Grant Type Included within Consolidated Statements of Operations and Comprehensive Loss (Detail) 100: R85 401 (K) PLAN - Additional Information (Detail) HTML 43K 101: R86 Summary of Other (Loss) Income, Net (Detail) HTML 56K 102: R87 Summary of Loss before Provision (Benefit) for HTML 42K Income Taxes by Jurisdiction (Detail) 103: R88 Summary of Provision (Benefit) for Income Taxes HTML 61K (Detail) 104: R89 Reconciliation Between Effective Tax Rate and HTML 54K Statutory Income Tax Rate (Detail) 105: R90 Income Taxes - Additional Information (Detail) HTML 69K 106: R91 Analysis of Deferred Tax Assets and Liabilities HTML 65K (Detail) 107: R92 Reconciliation of Beginning and Ending Amount of HTML 41K Unrecognized Tax Benefits (Detail) 108: R93 Leases - Additional Information (Detail) HTML 64K 109: R94 Summary of Lease Costs Recognized Under Topic 842 HTML 50K and Other Information Pertaining to Operating Leases (Detail) 110: R95 Summary of Maturities of Lease Liabilities and HTML 60K Reconciliation of Lease Liabilities Recognized Under Topic 842 (Detail) 111: R96 Net Loss Per Share - Basic and Diluted Net Loss HTML 72K Per Share (Detail) 112: R97 Net Loss Per Share - Basic and Diluted Net Loss HTML 41K Per Share (Parenthetical) (Detail) 113: R98 Commitments and Contingencies - Additional HTML 92K Information (Detail) 114: R99 Summary of Non-Cancelable Contractual Obligations HTML 45K Arising From Long-term Contractual Arrangements (Detail) 117: XML IDEA XML File -- Filing Summary XML 221K 115: XML XBRL Instance -- srpt-20221231_htm XML 5.15M 116: EXCEL IDEA Workbook of Financial Reports XLSX 265K 15: EX-101.CAL XBRL Calculations -- srpt-20221231_cal XML 323K 13: EX-101.DEF XBRL Definitions -- srpt-20221231_def XML 1.02M 14: EX-101.LAB XBRL Labels -- srpt-20221231_lab XML 2.28M 12: EX-101.PRE XBRL Presentations -- srpt-20221231_pre XML 1.71M 11: EX-101.SCH XBRL Schema -- srpt-20221231 XSD 343K 118: JSON XBRL Instance as JSON Data -- MetaLinks 690± 1.12M 119: ZIP XBRL Zipped Folder -- 0000950170-23-005062-xbrl Zip 1.23M
EX-10 |
Exhibit 10.72
Re: Amendments to Employment Agreement
Dear Doug:
This letter agreement (“Letter Agreement”) amends, effective on the date above, certain terms of the Employment Agreement (the “Employment Agreement”) dated June 26, 2017 between you and Sarepta Therapeutics, Inc. (the “Company”). This Letter Agreement is intended to relate to the Letter Agreement dated April 19, 2022 between you and the Company. Except as provided herein, the Employment Agreement will continue in accordance with its terms.
The noncompetition covenant set forth in Section 10(b) of the Employment Agreement will change such that the noncompetition covenant will extend until the later of (x) eighteen (18) months following the termination of your employment with the Company and (y) April 19, 2027.
To indicate your agreement with the foregoing, pleasesign and return this Letter Agreement to me. This Letter Agreement
will become effective as of the date on which you sign below.
Very truly yours,
SAREPTA THERAPEUTICS, INC.
By: /s/ Ryan Brown
Name: Ryan E. Brown
Title: SVP, General Counsel
Accepted and Agreed:
Name: Douglas S. Ingram
Date: November 18, 2022
[Signature Page to Letter Agreement]
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
4/19/27 | ||||
Filed on: | 2/28/23 | |||
For Period end: | 12/31/22 | 3, 4 | ||
11/18/22 | ||||
4/19/22 | 8-K | |||
6/26/17 | 3, 4, 8-K | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 2/28/24 Sarepta Therapeutics, Inc. 10-K 12/31/23 119:18M Donnelley … Solutions/FA |